Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$6.29 - $11.01 $857,842 - $1.5 Million
136,382 New
136,382 $1.13 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $16.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Endurant Capital Management LP Portfolio

Follow Endurant Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.